HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hyper-CVAD chemotherapy or autologous stem cell transplantation in patients with peripheral T cell lymphomas: a single centre report.

AbstractBACKGROUND:
Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy. The place for high-dose chemotherapy and autologous stem cell transplantation (ASCT) in these patients is still not clear. In this study, we presented the outcomes of PTCL patients followed these treatments in our centre.
METHODS:
We retrospectively analyzed the outcomes of 39 patients with PTCL received the two treatments between 1999 and 2010.
RESULTS:
The 3-year overall survival (OS) of 61.9% and 3-year progression free survival (PFS) of 35.7% were observed in the 39 patient. Twenty-one patients received Hyper-CVAD chemotherapy with 3-year OS of 46.2% and 3-year PFS of 27.9%. Eighteen patients received ASCT with 3-year OS of 70.3% and 3-year PFS of 44.2%. Further analysis revealed that patients with elevated lactate dehydrogenase, at least 2 international prognostic index (IPI) points, and extranodal involvement had a poorer outcome compared with the control group.
CONCLUSION:
These findings might suggest that Hyper-CVAD chemotherapy and ASCT could offer a durable survival benefit for patients with aggressive PTCL.
AuthorsYang Xu, Xiao-jin Wu, Ying Wang, Zheng-ming Jin, Ai-ning Sun, De-pei Wu
JournalChinese medical journal (Chin Med J (Engl)) Vol. 125 Issue 22 Pg. 4134-7 (Nov 2012) ISSN: 2542-5641 [Electronic] China
PMID23158157 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Vincristine
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
Topics
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cyclophosphamide (therapeutic use)
  • Dexamethasone (therapeutic use)
  • Doxorubicin (therapeutic use)
  • Female
  • Hematopoietic Stem Cell Transplantation (methods)
  • Humans
  • Lymphoma, T-Cell, Peripheral (drug therapy, therapy)
  • Male
  • Middle Aged
  • Retrospective Studies
  • Vincristine (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: